Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 05/06 12:59:23 pm
3790 GBp   -0.51%
05/05 ASTRAZENECA : *charles stanley raises astrazeneca to 'strong buy' ('..
05/05 ASTRAZENECA : Publication of a Prospectus
05/05 ASTRAZENECA : *berenberg cuts astrazeneca price target to 4950 pence..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ASTRAZENECA PLC
05/05 IRONWOOD PHARMACEUTICALS : Enters into U.S. Licensing Agreement with AstraZeneca..
05/05 ASTRAZENECA : *charles stanley raises astrazeneca to 'strong buy' ('buy')
05/05 ASTRAZENECA : Publication of a Prospectus
05/05 ASTRAZENECA : *berenberg cuts astrazeneca price target to 4950 pence - 'buy'
05/04 ASTRAZENECA : *hsbc cuts astrazeneca price target to 4240 pence - 'hold'
05/04 Innate Pharma First Quarter 2016 Report
05/03 AstraZeneca completes rights sale on Imdur; closes buy from Takeda Pharma
05/03 ASTRAZENECA : is cutting costs Drugmaker
05/03DJASTRAZENECA : Az completes acquisition of takeda respiratory
05/03 ASTRAZENECA : Completes divestment of imdur to china medical system holdings
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials